Member access

4-Traders Homepage  >  News

News

Latest NewsCompaniesMarketsEconomy & ForexCommoditiesHot NewsMost Read NewsRecomm.Business LeadersVideosCalendar 

Burzynski Clinic Presents Over Five Years Survival Data From Phase II Trials of ANP for Inoperable Brain Tumors at the Congress

11/15/2013 | 09:34pm US/Eastern

The Burzynski Clinic (BC) announced today that it made a keynote speaker presentation at the 2nd Annual Congress of Asia-Pacific Academy of Anti-Aging Medicine in Beijing, China. Based on the presentation in Beijing, a total of 401 eligible patients (patients who received over 28 days of treatment) with advanced inoperable brain tumors have been treated with antineoplaston A10 and antineoplastons AS2-1 therapy (ANP) in phase II studies. Most of the patients (87%) were diagnosed with high-grade tumors and the remaining patients were diagnosed with low-grade tumors. The patients were diagnosed by pathologists not associated with BC and objective responses were verified by Central Radiology Review. The group of 77 patients (19%) survived over five years from the treatment start. Of particular interest were results in patients with brainstem gliomas. The group of 17 patients with brainstem glioma underwent the treatment and 65% of these patients survived over five years. An additional group of 42 patients diagnosed with diffuse intrinsic pontine glioma (DIPG) have been treated and a total of 19% survived over five years.

The quality of survival is very good and there is no long-term toxicity related to ANP.

These clinical results are very encouraging, since they describe a positive ANP effect on some of the worst malignancies in the entire oncology field, but they will require FDA approval.

Burzynski Clinic is committed to developing treatments for cancer based on genomic and epigenomic principles.

Forward-looking statements in this release are made pursuant to the safe harbor provisions of the federal securities laws. Information contained in forward-looking statements is based on current expectations and is subject to change, and future events may differ materially from those discussed herein due to a number of factors, including, but not limited to, risks and uncertainties related to the clinic's ability to use Antineoplastons A10 and AS2-1. Burzynski Clinic does not undertake to update any such forward-looking statements or to publicly announce developments or events relating to the matters described herein.

For Burzynski Clinic
Carolyn Powers, 713-335-5664
carolyn@burzynskiclinic.com


© Business Wire 2013
React to this article
Latest news
Date Title
11:15pDJCITIGROUP : Citibank Reaches Pact With New York on ChexSystems Data
11:14p COMMERCE BANCSHARES : Fourth-quarter decline in Commerce earnings leads to a flat 2014
11:13p UMB FINANCIAL : reports a 22.3 percent drop in fourth-quarter earnings
11:09p MOSTOTREST : Construction of Alabyano-Baltiisky tunnel completed in Moscow
11:08p LENOVO : plans 20% acquisition of smart phone sales by end of March 2016: CEO
11:08p CHINA EASTERN AIRLINES : Heading from the Middle Kingdom to Middle Earth
11:08pDJAsian Shares Mostly Lower -- Update
11:07p CITIC SECURITIES : Profit of CITIC Securities doubles in 2014
11:07p Apple iPhone sales trample expectations
11:07p Ericsson on solid ground despite economic slowdown
Latest news
Advertisement
Hot News 
VOLGA GAS : Says No Longer For Sale; Costs To Fall In Line With Revenue
3LEGS RESOURCES : Proposes Cash Return, New Investment Policy To Avoid Liquidation (ALLISS)
STERLING CONSTRUCTION : Provides Preliminary Results for 2014 Fourth Quarter and Year
SILICON IMAGE : Lattice Semiconductor to Acquire Silicon Image for Approximately $600 Million
P2P GLOBAL INVESTMENTS : Raises GBP250 Million In C Share Issue (ALLISS)
Most Read News
06:58p Apple iPhone sales trample expectations as profit sets global record
08:13p Yahoo sets Alibaba stake spinoff plan, shares jump
10:38p Apple supplier Foxconn seeks to slim workforce over time, eyes robotics
07:04p AT&T results beat Wall Street, shares rise after hours
07:11p Canadian National Railway earnings beat, but lag CP on efficiency
Most recommended articles
11:08pDJAsian Shares Mostly Lower -- Update
10:57p BOMBARDIER EXPECTS NEW ORDERS AFTER CHINA HIGH-SPEED TRAIN SAFETY CLEARANCE : executive
10:38p Apple supplier Foxconn seeks to slim workforce over time, eyes robotics
10:27p Apple supplier Foxconn seeks to slim workforce over time, eyes robotics
10:22p Oil drops more than 1 percent on firm dollar, U.S. stock build
Dynamic quotes  
ON
| OFF